Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT04238624
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Anaplastic Thyroid Cancer
  • BRAF Gene Mutation
  • BRAF Mutation-Related Tumors
  • Thyroid Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dabrafenib — DRUG
    Participants will receive dabrafenib 150 mg orally twice a day
  • Trametinib — DRUG
    Participants will receive trametinib 2 mg orally once a day

Study Details

This study is being done to see if adding the study drug, cemiplimab, to the standard therapy with dabrafenib and trametinib is an effective treatment against anaplastic thyroid cancer.

Key Dates

Start date
Jan 20, 2020
Status verified
Jul 2025
Primary completion
Jun 20, 2026
Completion
Jun 20, 2026

Study Design

Enrollment
16 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BRAF-mutant ATC
    Participants will have a diagnosis of BRAF-V600E mutant Anaplastic Thyroid Cancer

Primary Outcome Measure

Overall Response Rate per RECIST 1.1 Criteria [ Time Frame: 2 years ]

Locations (7)

Find similar trials in Basking Ridge, NJ

Related Studies